1.22  -0.15 (-10.95%)		06-12 16:00
Open: 1.36 High: 1.38 Volume: 420,942		Pre. Close: 1.37 Low: 1.22 Market Cap: 22(M)

Short term
Mid term
Targets	6-month :	1.93	1-year :	2.25
Resists	First :	1.65	Second :	1.92
Pivot price	1.53
Supports	First :	1.22	Second :	1.01
MAs	MA(5) :	1.35	MA(20) :	1.53
	MA(100) :	1.19	MA(250) :	1.33
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	11.1	D(3) :	12.2
RSI	RSI(14): 38.4
52-week	High :	2.23	Low :	0.85

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NNVC ] has closed above bottom band by 6.0%. Bollinger Bands are 93% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.38 - 1.39	1.39 - 1.4
Low:	1.2 - 1.21	1.21 - 1.22
Close:	1.21 - 1.22	1.22 - 1.23

NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.

Mon, 08 Jun 2026
NanoViricides pushes chewable Ebola drug trial as Congo outbreak escalates - Stock Titan

Wed, 27 May 2026
NNVC Stock Draws Traders As NV-387 Targets Ebola, Measles - timothysykes.com

Wed, 27 May 2026
NNVC Stock Gains Attention As NV-387 Targets Ebola And Measles - StocksToTrade

Mon, 18 May 2026
Antiviral developer NanoViricides secures $2M from single institutional investor - Stock Titan

Fri, 15 May 2026
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II - ACCESS Newswire

Fri, 15 May 2026
Broad antiviral NV-387 drug candidate targets measles, mpox, smallpox - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.